AMX0035, an oral combination of two small molecules, sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA), is now being evaluated to determine if there is an impact on ALS disease progression. Each compound has shown efficacy in several cellular and animal models of ALS. Small clinical trials have supported the potential for safety and efficacy of these compounds; however, this larger trial is needed to confirm these findings.
Right now, doctors at select centers in the U.S. are accepting ALS patients to participate in the clinical research study for AMX0035. To learn more, please fill out the application below.
ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which leads to total paralysis and death, usually within two to five years of diagnosis.
Dr. Sabrina Paganoni from Massachusetts General Hospital discusses CENTAUR, a phase 2 trial for people with ALS.
The staff at your clinical trial site will help determine if you meet the criteria for the study. This study is looking for individuals who are:
Participating in the study will last for approximately 30-34 weeks, and includes:
The CENTAUR-OLE study provides patients with the option of continuing treatment once they have completed the 24-week study period.
The trial will evaluate AMX0035’s ability to have an impact on daily functioning, muscle strength, and respiratory function as well as its ability to alter biological markers of ALS.
For more information, fill out the form, contact (617-724-7210), or email Emily Engel at firstname.lastname@example.org